5:03 PM
 | 
Feb 12, 2018
 |  BC Extra  |  Company News

Axovant falls as CEO, president depart

Editor's Note: This article was updated on Feb 13, 2018 at 4:00 PM PST

Axovant Sciences Ltd. (NASDAQ:AXON) fell $0.38 (20%) to $1.54 on Monday after it shuffled its management team and board of directors. The neurology company said David Hung resigned as CEO and a director to pursue other opportunities. President and COO Marion McCourt also resigned as did board members Kate Falberg, Tony Vernon and Patrick Machado.

Hung, who will continue to serve as an advisor to the Roivant Sciences GmbH (Basel, Switzerland) family of companies, is succeeded by Pavan Cheruvu, a member of Roivant’s executive leadership team. Roivant is Axovant's majority owner.

Joining Axovant’s board are Roger Jeffs, former president and co-CEO of United Therapeutics Corp. (NASDAQ:UTHR), and George Bickerstaff, former CFO of Novartis AG (NYSE:NVS; SIX:NOVN).

Meanwhile, McCourt joined Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) as SVP and head of commercial.

The moves come a month after Axovant discontinued development of intepirdine (RVT-101), which missed the primary endpoints of the Phase IIb HEADWAY and Phase II Gait and Balance studies in patients with dementia (see BioCentury Extra, Jan. 8).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD